DC Chemicals · Product datasheet

FH535 — Datasheet

CAT. NO. DC7414

Product page and current package options

ParameterValue
Chemical NameN-(2-Methyl-4-nitrophenyl)-2,5-dichlorobenzenesulfonamide
CAS No.108409-83-2
SynonymsN-(2-Methyl-4-nitrophenyl)-2,5-dichlorobenzenesulfonamide;FH535;2,5-Dichloro-N-(2-methyl-4-nitrophenyl)benzenesulfonamide;FH-535;FH 535(FH-535);2,5-Dichloro-N-(2-methyl-4-nitrophenyl)benzenesulfonamide FH535;Tcf Inhibitor, FH535;β-Catenin;β-catenin and PPAR
FormulaC13H10N2O4Scl2
M.Wt361.2005
SMILESO=S(C1=CC(Cl)=CC=C1Cl)(NC2=CC=C([N+]([O-])=O)C=C2C)=O
Purity>98%
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

FH535 is an inhibitor of Wnt/β-catenin and PPAR, with anti-tumor activities.

In Vitro

FH535 is an inhibitor of Wnt/β-catenin and PPAR. FH535 inhibits PPARγ and PPARδ transactivation in HCT116 cells. FH535 (15 μM) activities depend on functional PPARδ but does not require a cysteine residue in the PPAR ligand-binding domain. FH535 inhibits recruitment of the coactivators GRIP1 and β-catenin to PPARδ and PPARγ. FH535 shows toxic effects on 12 carcinoma cell lines expressing wnt/β-catenin pathway[1]. FH535 (20 μM) suppresses the β-catenin pathway in pancreatic cancer cells, and inhibits pancreatic cancer cell migration. Furthermore, FH535 (20, 40 μM) inhibits pancreatic cancer cell invasion and cell growth[2]. FH535 represses angiogenesis-related genes in pancreatic cancer cells[3].

In Vivo

FH535 (25 mg/kg, i.p.) exhibits an anti-tumor effect on pancreatic cancer xenografts in mice. FH535 also represses angiogenesis in pancreatic cancer xenografts[2].

References & source

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

Cart

Request quotation